Unravelling Alzheimer’s: Innovations in Pathogenesis, Diagnosis, and Therapeutics

Alzheimer's Disease (AD) is a progressive neurodegenerative condition and the leading cause of dementia, marked by memory impairment, cognitive deterioration, and alterations in behaviour. Initially identified by Alois Alzheimer in 1906, the disorder has since garnered significant attention within the field of neuroscience. The defining pathological characteristics include the presence of extracellular amyloid-beta plaques, intracellular neurofibrillary tangles formed by hyperphosphorylated tau protein, and extensive neuronal degeneration. On a global scale, AD poses a considerable public health issue, currently affecting over 55 million individuals with dementia, a figure anticipated to rise beyond 139 million by 2050 due to the aging population. The disease predominantly impacts those aged 65 and older, with a higher incidence observed in women. Contributing factors to the development of AD encompass genetic vulnerabilities, such as mutations in the allele, alongside modifiable elements like cardiovascular health, educational attainment, and lifestyle choices. The economic and social ramifications of AD are significant, with an estimated annual global expenditure exceeding $1 trillion, which includes healthcare costs, caregiving expenses, and lost productivity. Furthermore, the emotional toll on families and caregivers is considerable, often resulting in psychological distress and financial hardship. Epidemiological research indicates variations in the prevalence and incidence of AD across different regions, shaped by demographic, cultural, and healthcare-related factors. Initiatives to combat AD include progress in early diagnostic methods utilizing biomarkers and neuroimaging, the creation of disease-modifying treatments, and public health strategies focused on prevention through the management of risk factors. This review seeks to present a comprehensive overview of the historical context, epidemiology, and global implications of AD, highlighting the pressing necessity for ongoing research and international cooperation to address this escalating crisis. 

Alzheimer’s Disease (AD), the leading cause of dementia worldwide, remains without an effective cure, largely due to an incomplete understanding of its underlying mechanisms. Recent research highlights the central roles of amyloid β (Aβ) and tau proteins, alongside glial cell dysfunction, in the pathogenesis of AD. This chapter reviews advances in Aβ- and tau-related mechanisms, focusing on neuronal and glial receptors mediating Aβ toxicity and the role of glial cells in neurodegeneration. Early neurodegeneration in AD is marked by neuronal loss and synaptic impairment. Despite significant progress in uncovering AD’s molecular mechanisms, the disease's complex pathogenesis and limited diagnostic and therapeutic tools have hindered the development of effective treatments. Comprehensive disease modelling is imperative to clarify AD’s mechanisms and facilitate the creation of targeted therapies. Mitochondrial dysfunction, oxidative stress, and chronic neuroinflammation emerge as critical mediators of neuronal damage, emphasizing the multifactorial nature of AD. This chapter reviews the interplay between inherited risk, aging, lifestyle factors, and environmental exposures in influencing AD pathogenesis. Additionally, it will explore how these factors contribute to the broader molecular and cellular pathways involved in disease progression. Microglial activation and astrocytic dysfunction significantly influence the progression of neuronal injury and synaptic loss, underscoring their importance in AD pathogenesis. Emerging evidence underscores the importance of understanding glial contributions to neuronal dysfunction, offering new perspectives on disease progression and potential intervention points. The transition from early-stage molecular alterations to widespread neuronal dysfunction and clinical decline underscores the importance of early pathophysiological insights. Recent advancements in understanding AD’s complex pathophysiology provide promising avenues for enhanced diagnostics, assessing risks more accurately, and novel prevention strategies. These discoveries bring hope for improved management and therapeutic options for the millions affected by this debilitating condition.

Alzheimer's Disease (AD) is a multifactorial neurodegenerative disease associated with progressive decline in cognitive functions. Recent advances have been made in diagnostic techniques for AD by using Biomarkers. Biomarkers are not mere indicators of their pathophysiology but are the key to optimizing and making clinical decisions and therapeutic strategies. Biomarkers have thus become crucial elements in the diagnosis, monitoring, and treatment of AD. Early detection of AD is also essential for interventions, and biomarkers in AD, such as the development of senile plaques through aggregation of amyloid-beta and neurofibrillary tangle formation through tau proteins, and in recent years, new trends have been made towards the detection of Ocular biomarkers are considered important contributors in the diagnosis of AD. Ocular biomarker is an important biomarker because the nervous system of the eyes is considered an extension of the CNS. So, biomarkers help in distinguishing the cause of dementia in cognitive disorders like AD and thereby provide a target for therapeutic strategies. As the disease progresses, levels of biomarkers can be monitored for clinical manifestation, thus informing healthcare providers about disease trajectories in patients and changing the therapeutic approach correspondingly. “For instance, via examination of the cerebrospinal fluid, neuroimaging, or related techniques, valuable information on the pathology of AD may be obtained, which helps in tracking neurocognitive decline. Biomarkers also play a critical role in the assessment of treatment efficacy”. Objective measures, reduction in amyloid burden as measured by PET scans, can be an indication of good response to amyloid-targeting therapies and direct further treatment. Further studies on new biomarkers, including neuroinflammatory markers and genetic variants, will provide further refinement of personalized treatment approaches, thereby helping improve the outcomes of the patients. To enhance the appropriate early diagnosis and proper monitoring plus targeted treatment interventions, these biomarkers should be integrated into the clinical care of AD. It is now clear from other various studies that this might change the way AD is treated and improve the standard of care. 

Globally, dementia is a major cause of death and disability. The early, precise, and differential diagnosis of dementia and Alzheimer’s disease depends on neuroimaging or brain imaging. Because of structural and molecular imaging, which is also increasingly being employed in clinical practice for early and accurate diagnosis, the pathogenesis of neurodegenerative dementias has been better understood. Several neuroimaging techniques that are regarded as state-of-the-art diagnostic aids were highlighted. Most of the research that uses imaging modalities for early diagnosis is preventive studies. The accurate identification of AD biomarkers is made possible by AI-enhanced neuroimaging methods such as MRI, PET, and CT scans. With technologies that improve the precision of neuropsychological testing and examine speech and language patterns for early indicators of dementia, artificial intelligence has also enhanced cognitive and behavioural examinations. The MRI modalities discussed encompass structural MRI, functional MRI, diffusion tensor imaging, magnetic resonance spectroscopy, and arterial spin labelling. These advanced techniques enable the identification of presymptomatic diagnostic biomarkers in the brains of cognitively normal older adults and can also be utilized to track Alzheimer's disease progression following the emergence of clinical symptoms. Advanced MRI techniques, such as arterial spin labelling and Diffusion Tensor Imaging (DTI), are also being explored to better understand Alzheimer's disease. In PET imaging, ongoing efforts focus on developing high selectivity and affinity ligands. As no single imaging method is adequate for early diagnosis, this has led to the emergence of a new approach known as “multi-modal imaging.”

The integration of digital tools and Artificial Intelligence (AI) has brought significant advancements to the diagnosis of various diseases, particularly neurodegenerative disorders like Alzheimer’s disease. AI, particularly Machine Learning (ML), enables the analysis of vast and complex datasets, such as neuroimaging, electronic health records, cognitive assessments, and biomarkers, which are crucial for early detection and accurate diagnosis. These technologies offer the potential to identify subtle changes in patients' conditions over time, improving the precision of diagnosis and facilitating the development of personalized treatment plans. Digital tools, including wearable devices, mobile applications, and fitness trackers, allow for continuous and passive monitoring of patient data, providing real-time insights into physiological parameters like gait, heart rate, and brain activity. These tools can detect early signs of cognitive decline and other abnormalities, aiding clinicians in making more informed decisions about disease progression. AI has demonstrated its potential in automating image analysis, identifying biomarkers, and predicting disease progression, which can expedite the diagnostic process and enhance the overall healthcare experience. Additionally, AI-driven models can integrate data from multiple sources, enabling comprehensive assessments and more accurate predictions about the onset and development of diseases like AD. However, there are several challenges associated with the widespread adoption of AI in clinical settings, such as concerns about data quality, model interpretability, ethical considerations, and cost. Overcoming these barriers is essential to ensuring that AI technologies become accessible, reliable, and effective in healthcare. This chapter explores the transformative potential of AI and digital tools in diagnostics, discussing their applications, benefits, challenges, and the future directions for improving patient care and outcomes. 

Alzheimer’s Disease (AD) is a progressive neurodegenerative condition that primarily impairs memory, cognition, and behavioural functions. Since no definitive cure currently exists, increasing attention has shifted toward lifestyle interventions and nutraceutical supplementation as supportive strategies for prevention and symptom management. Nutraceuticals such as polyphenols, omega-3 fatty acids, antioxidants, and vitamins have shown promise in alleviating oxidative stress, neuronal inflammation, and age-related neurodegeneration processes strongly implicated in AD pathology. Compounds like curcumin, resveratrol, and docosahexaenoic acid (DHA) have demonstrated neuroprotective properties in preclinical and clinical studies, suggesting their potential in moderating cognitive decline and supporting brain health. Lifestyle-based approaches, including regular physical activity, cognitive exercises, and dietary modifications, further enhance protective outcomes. Exercise promotes neuroplasticity, optimises cognitive performance, and reduces dementia risk, while social engagement and mental stimulation strengthen resilience to cognitive impairment. Nutritional patterns such as the Mediterranean diet, rich in plant-based foods and healthy fats, are associated with a reduced risk of developing AD, highlighting the significant role of diet in maintaining neural function. Although ongoing research continues to explore optimal doses, duration, and mechanisms of these approaches, integrating nutraceuticals with lifestyle modifications offers a practical and holistic strategy to delay or minimise AD progression and improve quality of life in at-risk individuals.

Globally, Alzheimer's Disease (AD) is the most common neurological disorder that affects the older population. However, the intricacy of AD pathophysiology causes disparities in our knowledge of the disease and could be the primary cause of the medication development failure for AD. Thankfully, several preclinical and clinical research projects are still in progress, which will continue to pave the way for the discovery of disease processes and direct approaches to AD diagnosis and medication development. For instance, because of the exceptional preclinical outcomes, immunotherapeutic approaches targeting the tau and amyloid-β (Aβ) proteins were originally thought to be almost successful in clinical treatment. This strategy has been called into question due to the numerous failures in clinical studies involving vaccinations and humanized anti-tau monoclonal, anti-Aβ antibodies. However, immunotherapy targeting Aβ may still have potential, as evidenced by the United States Food and Drug Administration (USFDA) recent endorsement of Aducanumab, a novel anti-Aβ monoclonal antibody. Immunotherapies targeting various targets, including microglia, tau, and the gut-brain axis, are also being developed in the meantime. To improve the accuracy and efficacy of immunotherapeutic treatments, more inspection is required to clarify the targeted proteins' structures and epitopes. In this review, we concentrate on the mechanisms of action of immunotherapies focused on microglia, tau, and Aβ in AD. We also discuss current developments and prospects for immunotherapeutic approaches to AD.

Gene therapy is the process of transferring genetic material to treat a disease or, at the very least, to enhance a patient's clinical condition. Gene therapy can be implemented by transforming viruses into genetic carriers that deliver the desired gene to the target cells. Depending on the kind of genome, these vectors can be classified as either DNA-based or RNA-based viral vectors. Gene therapy holds promise for treating illnesses that traditional medicine cannot address. To apply it, a patient's cells must receive one or more nucleic acids or a faulty gene. Clinical gene therapy has advanced significantly during the past ten years. One can list several noteworthy achievements, including the development of medicines for diabetes, Alzheimer's, Parkinson's, cystic fibrosis, and several types of cancer. Long-term studies on the therapy of Alzheimer's disease have led to the development of various drugs, such as monoclonal antibodies to Aβ aggregation, cholinesterase inhibitors, and inhibitors of tau aggregation. Researchers continued to work on the disease even though the drugs did not stop its advancement, and as a result, gene therapy, a recently developed, state-of-the-art technique for delivering genes to specific locations where they can express the desired functionalities, is being introduced. For AD, gene therapy is a promising diseasemodifying treatment. “Protein-coding and noncoding RNAs make up between 70 and 90 percent of the human genome. These RNAs are the primary determinants of biological variation in cells and populations. Among the different kinds of nucleic acids, RNA is more adaptable than DNA because of its single-stranded structure, direct protein-encoding capability, and high degree of modification for specific regulatory and therapeutic uses. Even with its bright future in biomedicine, RNA-based therapy still has several obstacles to overcome. Notably, delivering RNA effectively and precisely while reducing immunological reactions is one of the biggest technical challenges. Viral vectors, Virus-Like Particles (VLPs), lipid nanoparticles (LNPs), and Extracellular Vesicles (EVs) are some of the methods that have been created for delivering RNA. 

Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder that primarily affects cognitive and functional abilities. While much study has focused on the basic pathology of AD, the role of comorbidities in influencing its progression has gained increasing attention. Comorbidities, such as cardiovascular diseases, diabetes, depression, and sleep disorders, are highly prevalent in individuals with AD and significantly impact its trajectory, outcomes, and management. This chapter focuses on the intricate interplay between Alzheimer’s disease and common comorbid conditions, highlighting how these comorbidities contribute to faster cognitive decline, worsened behavioral symptoms, and increased caregiver burden. Key mechanisms linking comorbidities to AD progression, including chronic inflammation, vascular dysfunction, metabolic dysregulation, and oxidative stress, are discussed in detail. These processes increase neuronal damage and can accelerate the formation of amyloid-beta and tau proteins, indicators of AD pathology. The chapter also addresses the clinical challenges posed by comorbidities in AD patients, such as diagnostic complexities, polypharmacy, and the lack of tailored management guidelines. Practical strategies for effective management are outlined, including comprehensive assessments, personalized care plans, and the merging of pharmacological and nonpharmacological treatments. The role of multidisciplinary teams in optimizing patient outcomes is emphasized, along with emerging research into novel therapeutic targets and biomarkers for early detection and intervention. This chapter aims to provide a significant resource for healthcare practitioners, researchers, and caregivers, promoting a more complete approach to managing Alzheimer’s disease in the presence of comorbidities. 

Alzheimer's disease is a complicated neurological disease characterized by behavioural defects, memory loss, and progressive cognitive deterioration. Recent developments in pharmaceutical innovation have demonstrated promise in tackling fundamental pathogenic pathways, such as neuroinflammation, synaptic dysfunction, mitochondrial impairments, amyloid-\u03B2 and more. Notable strategies include synapse-restoring medicines, tau aggregation inhibitors, neuroinflammatory modulators, and monoclonal antibodies that target amyloid-β2 aggregates. Therapeutic possibilities are further enhanced by emerging methods such as gene editing and RNAbased therapeutics, as well as biomarkers for personalized medicine. These developments provide fresh optimism for altering the course of the disease and enhancing patient outcomes, even though issues like safety profiles and efficient delivery methods still exist. While tau aggregation inhibitors and anti-tau antibodies are being studied to reduce the formation of neurofibrillary tangles, monoclonal antibodies such as aducanumab and lecanemab have shown potential in reducing the amyloid plaque burden. Neuroinflammation is a key player in the widespread pathology of Alzheimer’s disease, and drugs that alter microglial activity or stop pro-inflammatory cytokines such as TNF-α and IL-1β are used to combat it. Due to growing understanding of the meaning of mitochondrial dysfunction, mitophagy activators and mitochondrial protectants have been developed to preserve the energy balance of neurons. Gene and RNA-based therapies may hold promise for precision medicine, including CRISPR/Cas9 editing and antisense oligonucleotide platforms that allow us to correct protein expression and genetic factors to more precisely address genetic and phenotypic variables. Moreover, advances in imaging and fluid biomarkers are enabling more personalized treatment plans and improved early detection. Though challenges still remain, including in managing side effects and delivering medications across the blood-brain barrier, these developments represent a significant breakthrough in the fight against Alzheimer’s. Future efforts must prioritize cross-disciplinary approaches integrating lifestyle shifts with pharmaceutical advancements to enable complete illness remediation.

Alzheimer’s disease is a long-term, neurodegenerative disease of the brain, which is a major cause of dementia affecting the elderly population. It is also characterised by behavioural dysfunction and cognitive impairment. Alzheimer’s disease is a complex disease involving multiple genetic and environmental risk factors. Despite significant advancements in the study of Alzheimer's disease, many aspects of the disease are still poorly understood. Although a reduction in acetylcholine and the formation of amyloid-beta plaques are characteristic signs of Alzheimer's disease, the precise causes and mechanisms underlying the illness are still unknown. Significant reduction of neurotransmitters, such as acetylcholine and butyrylcholine, and aggregation of β-amyloid protein in the neocortex of the brain are strongly linked to the etiology of Alzheimer's disease. Although there is currently no treatment for Alzheimer's, both pharmaceutical and non-pharmacological therapy options are being thoroughly studied. Recent research has introduced promising new drugs designed to address the root causes of AD. Acetylcholinesterase inhibitors (e.g., donepezil) and NMDA receptor antagonists (e.g., memantine) are used for symptomatic relief. Donepezil was the first cholinesterase inhibitor drug approved for the symptomatic treatment of Alzheimer’s disease. Later, other drugs, such as rivastigmine and galantamine, also got FDA approval. Newly FDA-approved drugs, such as Aducanumab and Lecanemab, have been effective in reducing amyloid plaques. Many hybrid molecules targeting two or more relevant sites of disease have been developed and tested. These hybrid compounds showed antiinflammatory and amyloid aggregation inhibition. Additionally, many global clinical trials are underway testing effective therapies for Alzheimer’s disease. Current therapies can control symptoms, but they cannot halt or reverse the disease's course. Researchers are now focusing on target the molecular mechanisms that underlie Alzheimer’s disease. This chapter examines the most recent therapeutic approaches targeted at amyloid plaques, tau protein tangles, neurotransmitter imbalances, anneuro inflammation.

Alzheimer's disease is a monogenic brain illness that impairs thinking, remembrance, judgment, and focus, making it difficult for an individual to carry out regular responsibilities. Drug delivery to the brain is necessary for the effective treatment of diseases of the CNS, including epilepsy, schizophrenia, meningitis, migraine, Parkinson's disease, and Alzheimer's disease. However, because the BloodBrain Barrier (BBB) separates the Central Nervous System (CNS) from the rest of the body, this remains a challenging area to manage. The blood-brain barrier and additional barriers to oral and other routes, such as decreased bioavailability, quick metabolism, rapid excretion, and drug breakdown by enzymes and stomach juices, make it difficult to transfer drugs to the brain. Promising drug delivery strategies for the efficient nasal delivery of anti-Alzheimer medications with enhanced permeability and bioavailability include lipid particle systems, emulsion-based systems, vesicular drug delivery systems, and other nanocarriers. Effective and targeted drug administration via the nasal route is influenced by charge, size, neurotherapeutic type, and formulation excipients. One of the cutting-edge approaches to brain targeting being explored to overcome the limitations of oral and other modes of administration is the nose-to-brain medication delivery device. A promising substitute for administering medications and enhancing the therapy of Alzheimer's disease is the intranasal route, through the olfactory and trigeminal pathways in the nasal cavity. Intranasal delivery provides a direct channel to the brain. Nasal physiology, however, can restrict bioavailability and impede drug absorption. Despite being limited by the particular circumstances of the nasal canal, intranasal administration has become a viable option. Using nanotechnology-based nano-carriers for intranasal delivery is a novel strategy. By offering increased bioavailability, greater permeability, efficient blood-brain barrier traversal, prolonged retention inside the body, and precise brain targeting, this approach may be able to get past the present restrictions. Therefore, it is necessary to use technical solutions to maximize the physicochemical features of formulations.

Alzheimer's disease is a progressive neurodegenerative disorder that affects cognition, memory, and neuronal loss. Treatment strategies remain largely underdeveloped, despite numerous studies. The chapter reviews the most recent case studies and patents to further novel therapeutic approaches in the treatment of AD. Case studies can depict the potential to exemplify the patient's response in the course of such therapy, where personal treatment choices are considered in conjunction with the efficacy of newly introduced therapies. Patents are the indicators of innovative drug discovery, biomarkers, and neuroprotective strategies. We focus on patents covering Multi-Target Directed Ligands (MTDLs), monoclonal antibodies, and small molecules targeting amyloid-beta (Aβ) and tau proteins. We also scan patents centered around cholinesterase inhibitors, neuroinflammation modulators, and techniques in gene therapy. Case studies that involve success stories of drug development in clinical settings, along with personalized medicine approaches, are also examined. New biotechnological interventions like drug delivery systems via nanotechnology and AIbased diagnostic tools are emerging to transform AD treatment. Furthermore, regulatory policies and intellectual property rights also create an atmosphere conducive to speeding or slowing the commercialization of innovative products for AD. Within view, this chapter gives an integrated view of current patents with a case study of the management of AD concerning their real-world applications, as well as current discoveries in its management.